We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Self-triggered thermoelectric nanoheterojunction for cancer catalytic and immunotherapy.
- Authors
Yuan, Xue; Kang, Yong; Dong, Jinrui; Li, Ruiyan; Ye, Jiamin; Fan, Yueyue; Han, Jingwen; Yu, Junhui; Ni, Guangjian; Ji, Xiaoyuan; Ming, Dong
- Abstract
The exogenous excitation requirement and electron-hole recombination are the key elements limiting the application of catalytic therapies. Here a tumor microenvironment (TME)-specific self-triggered thermoelectric nanoheterojunction (Bi0.5Sb1.5Te3/CaO2 nanosheets, BST/CaO2 NSs) with self-built-in electric field facilitated charge separation is fabricated. Upon exposure to TME, the CaO2 coating undergoes rapid hydrolysis, releasing Ca2+, H2O2, and heat. The resulting temperature difference on the BST NSs initiates a thermoelectric effect, driving reactive oxygen species production. H2O2 not only serves as a substrate supplement for ROS generation but also dysregulates Ca2+ channels, preventing Ca2+ efflux. This further exacerbates calcium overload-mediated therapy. Additionally, Ca2+ promotes DC maturation and tumor antigen presentation, facilitating immunotherapy. It is worth noting that the CaO2 NP coating hydrolyzes very slowly in normal cells, releasing Ca2+ and O2 without causing any adverse effects. Tumor-specific self-triggered thermoelectric nanoheterojunction combined catalytic therapy, ion interference therapy, and immunotherapy exhibit excellent antitumor performance in female mice. The exogenous excitation requirement and electron-hole pair recombination are the key factors limiting the application of catalytic therapies. Here, the authors address these limitations by designing a tumor microenvironment-specific self-triggered thermoelectric nanoheterojunction with a self-built-in electric field that facilitates charge separation for cancer treatment.
- Subjects
REACTIVE oxygen species; ELECTRON-hole recombination; THERMOELECTRIC effects; IMMUNOTHERAPY; ELECTROPORATION therapy; TUMOR antigens; ANTIGEN presentation
- Publication
Nature Communications, 2023, Vol 14, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-023-40954-y